Other Cancer Vaccine candidates being pursued by Inovio are: (a) V930, a DNA vaccine being developed in partnership with Merck, which is designed to target cancers expressing the antigens HER-2/neu and/or CEA (ID: NCT00250419); (b) V934, a DNA plasmid, also being developed in partnership with Merck that encodes human Telomerase (hTERT) (ID: NCT00753415). The gene discussed is CEACAM5; the disease is cancer.